Spots Global Cancer Trial Database for mtor inhibitor
Every month we try and update this database with for mtor inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00622258 | Non-Hodgkin's L... | Everolmus | 20 Years - | Novartis | |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | NCT01495247 | Inoperable Loca... Metastatic Brea... | BEZ235 Paclitaxel | 18 Years - | Novartis | |
| Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma | NCT01684449 | Advanced Soft T... | Gemcitabine + R... | 18 Years - 70 Years | Grupo Espanol de Investigacion en Sarcomas | |
| A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | NCT02019693 | Kidney Cancer | INC280 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | NCT01713946 | Tuberous Sclero... | RAD001 Placebo Antiepileptic d... open label RAD0... | 2 Years - 65 Years | Novartis | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | NCT02019693 | Kidney Cancer | INC280 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | NCT01343498 | Malignant Solid... | BEZ235 | 18 Years - | SCRI Development Innovations, LLC | |
| Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | NCT02596828 | Pineoblastoma | Temozolomide Irinotecan Dasatinib Rapamycin | 0 Years - 25 Years | University of Regensburg | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | NCT02596828 | Pineoblastoma | Temozolomide Irinotecan Dasatinib Rapamycin | 0 Years - 25 Years | University of Regensburg | |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | NCT01467986 | Neuroblastoma R... | Dasatinib Rapamycin Irinotecan Temozolomide Irinotecan Temozolomide | - 25 Years | University of Regensburg | |
| A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00622258 | Non-Hodgkin's L... | Everolmus | 20 Years - | Novartis | |
| Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T | NCT02332902 | Neurofibromatos... | Everolimus | 18 Years - | The University of Texas Health Science Center, Houston | |
| Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC | NCT05495425 | Tuberous Sclero... | NPC-12Y gel NPC-12Y placebo... | 3 Years - | Nobelpharma | |
| Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer | NCT01298713 | Breast Neoplasm... mTor Protein | Tamoxifen Everolimus | 18 Years - | ARCAGY/ GINECO GROUP | |
| Sirolimus for Cowden Syndrome With Colon Polyposis | NCT04094675 | PTEN Gene Mutat... PTEN Hamartoma ... PTEN Hamartoma ... Cowden Syndrome Bannayan Syndro... Bannayan Zonana... Polyposis | Sirolimus | 18 Years - 80 Years | Ohio State University | |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | NCT02008877 | Malignant Perip... Sarcoma | ganetespib Sirolimus | 16 Years - | Sarcoma Alliance for Research through Collaboration | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | NCT01713946 | Tuberous Sclero... | RAD001 Placebo Antiepileptic d... open label RAD0... | 2 Years - 65 Years | Novartis | |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | NCT01467986 | Neuroblastoma R... | Dasatinib Rapamycin Irinotecan Temozolomide Irinotecan Temozolomide | - 25 Years | University of Regensburg | |
| Sirolimus for Cowden Syndrome With Colon Polyposis | NCT04094675 | PTEN Gene Mutat... PTEN Hamartoma ... PTEN Hamartoma ... Cowden Syndrome Bannayan Syndro... Bannayan Zonana... Polyposis | Sirolimus | 18 Years - 80 Years | Ohio State University | |
| Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma | NCT01684449 | Advanced Soft T... | Gemcitabine + R... | 18 Years - 70 Years | Grupo Espanol de Investigacion en Sarcomas | |
| A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | NCT01713946 | Tuberous Sclero... | RAD001 Placebo Antiepileptic d... open label RAD0... | 2 Years - 65 Years | Novartis | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI | NCT01797120 | Metastatic Brea... | Fulvestrant Everolimus Placebo | 18 Years - | PrECOG, LLC. | |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | NCT01661283 | Malignant Perip... MPNST Sarcoma | everolimus bevacizumab | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | NCT01661283 | Malignant Perip... MPNST Sarcoma | everolimus bevacizumab | 18 Years - | Sarcoma Alliance for Research through Collaboration |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
